Sign In
Buy TNDM
$19.50
+0.490 (+2.58%)
At Close: Jul 31, 2026
TNDM Q4 Earnings & Revenues Beat Estimates, Gross Margin & Stock Up
10:16am, Friday, 20'th Feb 2026
Tandem Diabetes tops Q4 estimates with narrower loss, 15% revenue jump and wider gross margin, sending shares up 6.7% after hours.
Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript
02:24am, Friday, 20'th Feb 2026
Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript
Tandem Diabetes Care (TNDM) Reports Q4 Earnings: What Key Metrics Have to Say
07:00pm, Thursday, 19'th Feb 2026
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key m
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Tops Revenue Estimates
06:21pm, Thursday, 19'th Feb 2026
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.44 per share a year ago.
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
04:05pm, Thursday, 19'th Feb 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year e
Unlocking Q4 Potential of Tandem Diabetes Care (TNDM): Exploring Wall Street Estimates for Key Metrics
10:16am, Tuesday, 17'th Feb 2026
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Tandem Diabetes Care (TNDM), delve into some of its key metrics to gain a deeper insight into the company's potential performanc
Tandem Diabetes Care Announces Upcoming Conference Presentations
04:05pm, Thursday, 12'th Feb 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes C
New York, New York--(Newsfile Corp. - February 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tan
Bryce Point Capital LLC Purchases Shares of 42,258 Tandem Diabetes Care, Inc. $TNDM
04:00am, Tuesday, 10'th Feb 2026
Bryce Point Capital LLC acquired a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) in the undefined quarter, according to the company in its most recent Form 13F filing with the Se
NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes C
New York, New York--(Newsfile Corp. - February 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tand
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
06:30am, Saturday, 07'th Feb 2026
NEW YORK, Feb. 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, I
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes C
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Recommendation of “Hold” from Brokerages
02:53am, Thursday, 05'th Feb 2026
Tandem Diabetes Care, Inc. (NASDAQ: TNDM - Get Free Report) has received a consensus recommendation of "Hold" from the eighteen ratings firms that are covering the firm, Marketbeat Ratings reports. On
